Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Seagen Inc.
PMV Pharmaceuticals, Inc
Kivu Bioscience Inc.
STORM Therapeutics LTD
Eli Lilly and Company
Terremoto Biosciences Inc.
Jazz Pharmaceuticals
AstraZeneca
Seagen Inc.
Radiopharm Theranostics, Ltd
Arvinas Inc.
Tizona Therapeutics, Inc
Normunity AccelCo, Inc.
IDEAYA Biosciences
MacroGenics
SystImmune Inc.
Daiichi Sankyo
Solve Therapeutics
Adela, Inc
Radiopharm Theranostics, Ltd
Second Life Therapeutics
Elephas
Fusion Pharmaceuticals Inc.
Elephas
GlaxoSmithKline
Fate Therapeutics
Tanabe Pharma America, Inc.
NeoTX Therapeutics Ltd.
Volastra Therapeutics, Inc.
Tempus AI
Incyte Corporation
LigaChem Biosciences, Inc.
Merck Sharp & Dohme LLC
Bolt Biotherapeutics, Inc.
Tempest Therapeutics
Guardant Health, Inc.
Exelixis
Incyte Corporation
Merck Sharp & Dohme LLC
Totus Medicines
Marengo Therapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
Klus Pharma Inc.
Tempus AI
Theratechnologies
Checkpoint Therapeutics, Inc.
Aminex Therapeutics, Inc.
Carisma Therapeutics Inc
NextCure, Inc.